LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Actin and microtubule cytoskeletons are crucial for cancer cell proliferation.
• Microtubule-targeting drugs are common cancer therapies but face toxicity challenges.
• LIM kinases regulate cytoskeletal dynamics and are potential therapeutic targets.

Purpose of the Study:

• To investigate LIM kinase inhibition as a strategy to enhance cancer therapy efficacy.
• To identify effective drug combinations involving LIM kinase inhibitors.
• To develop novel LIM kinase inhibitors and assess their anti-cancer activity.

Main Methods:

• Utilized a previously described LIM kinase inhibitor (LIMKi) in combination studies.
• Screened LIMKi with 366 kinase inhibitors to identify synergistic combinations.
• Developed novel LIMK inhibitors (CRT0105446, CRT0105950) and evaluated their in vitro and cellular activity.
• Performed large-scale screening of novel inhibitors against 656 cancer cell lines.

Main Results:

• LIMKi induced mitotic defects and enhanced the cytotoxicity of microtubule polymerization inhibitors.
• Effective combinations were found with EGFR, p38, and Raf kinase inhibitors.
• CRT0105446 and CRT0105950 potently inhibit LIMK1/2, reduce cofilin phosphorylation, and increase αTubulin acetylation.
• Rhabdomyosarcoma, neuroblastoma, and kidney cancer cell lines showed significant sensitivity to both novel LIMK inhibitors.

Conclusions:

• LIM kinase inhibition can overcome limitations of current microtubule-targeting cancer therapies.
• Novel LIMK inhibitors CRT0105446 and CRT0105950 demonstrate potent anti-cancer activity.
• Specific cancer types, including rhabdomyosarcoma, neuroblastoma, and kidney cancer, are sensitive to LIMK inhibition.
• These findings support the further development of LIMK-targeted cancer therapies.